Free tool
FAERS Monitor: Ilaris
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125319 or its brand name (Ilaris, Canakinumab). Reports on generic versions are filed under their own applications.
Reports
10,910
Serious
5,167
47% of reports
Hospitalization
2,449
Death reported
489
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pyrexia1,442
- drug ineffective1,242
- inappropriate schedule of drug administration1,242
- inappropriate schedule of product administration966
- pain946
- condition aggravated876
- off label use751
- malaise731
- arthralgia613
- rash571
- incorrect dose administered506
- joint swelling492
- headache445
- fatigue400
- pulmonary embolism391
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 9 |
| 2011 | 61 |
| 2012 | 188 |
| 2013 | 98 |
| 2014 | 143 |
| 2015 | 493 |
| 2016 | 956 |
| 2017 | 1,421 |
| 2018 | 1,130 |
| 2019 | 985 |
| 2020 | 1,206 |
| 2021 | 734 |
| 2022 | 1,021 |
| 2023 | 972 |
| 2024 | 632 |
| 2025 | 521 |
| 2026 | 339 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,249 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| inappropriate schedule of drug administrationSignal | 1,242 | 34.2 | 32.5 | 39,477 |
| inappropriate schedule of product administrationSignal | 966 | 10.4 | 9.8 | 8,209 |
| pyrexiaSignal | 1,442 | 8.1 | 7.7 | 9,027 |
| pulmonary embolismSignal | 391 | 8.0 | 7.2 | 2,374 |
| joint swellingSignal | 492 | 7.9 | 7.2 | 2,956 |
| condition aggravatedSignal | 876 | 5.6 | 5.2 | 3,317 |
| incorrect dose administeredSignal | 506 | 4.3 | 3.9 | 1,280 |
| malaiseSignal | 731 | 3.2 | 3.0 | 1,136 |
| painSignal | 946 | 3.0 | 2.8 | 1,271 |
| arthralgiaSignal | 613 | 2.8 | 2.6 | 745 |
| rashSignal | 571 | 2.5 | 2.3 | 536 |
| drug ineffective | 1,242 | 1.8 | 1.7 | 486 |
| off label use | 751 | 1.7 | 1.5 | 202 |
| headache | 445 | 1.4 | 1.2 | 45 |
| fatigue | 400 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.